Your request has been received.
We will send you more information as it becomes available.
days to go: ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
Pacira BioSciences, Inc. has prepared this information in good faith based on current information reasonably available. No liability whatsoever is accepted and no representation, warranty or undertaking, express or implied, is or will be made by Pacira or any of Pacira's affiliates, or any of their respective agents, directors, officers, employees, advisers, or representatives ("Agents"), for any information, projections, or any of the opinions contained herein, or for any errors, omissions or misstatements. Neither Pacira nor any of Pacira's affiliates, nor any of their respective Agents makes or has authorized to be made any representations or warranties (express or implied) in relation to Pacira or this website or as to the truth, accuracy or completeness of the information contained on this website, or any other written or oral statement provided in connection herewith, (the "Data").
Neither the issue of the Data nor any part of its contents constitutes an offer to sell or invitation to purchase any of the products or services or assets described herein or any of the same relating thereto (the "Products"), and no information set out in the Data or referred to in any other written or oral information provided in connection with the Products is intended to form the basis of any decision to enter into any agreement or transaction with respect to the Products. Neither the issue of the Data nor any part of its contents is to be taken as any form of commitment on the part of Pacira or any of Pacira's affiliates, nor any of their respective Agents to proceed with any agreement or transaction with respect to the Products.
Neither Pacira nor any of Pacira's affiliates, nor any of their respective Agents undertakes any obligation to provide you or any other party with access to any additional information or to update or correct any inaccuracies in or omissions with respect to the Data, and the right is reserved, without giving reason, at any stage and in any respect to amend any content or proposed timetable, and to terminate any procedure or discussions or negotiations with you or any prospective purchaser.
In no circumstances will Pacira nor any of Pacira's affiliates, nor any of their respective Agents be responsible for any costs or expenses incurred in connection with any appraisal or investigation of the Products or the viewing or use of the Data, or for any other costs and expenses incurred by you or any prospective purchasers in connection with any agreement or transaction related thereto.
The Data should not be considered as a recommendation by Pacira, nor any of Pacira's affiliates, nor any of their respective Agents to enter into any agreement or transaction related to the Products or for the viewing or use of the Data. You are recommended to seek your own scientific, clinical, medical, financial and other advice as you, in your sole discretion, deem necessary and appropriate and should rely solely on your own judgment, review and analysis in evaluating the Data and Products.
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.